Patent search ap:("UNIV HEALTH NETWORK") AND inv:"BRAY MARK ROBERT" Page 1

1.

发明专利
CRYSTAL FORM S4 OF THE PLK4 INHIBITOR (1R,2S)-(E)-2-(3-(4-((CIS-2,6-DIMETHYLMORPHOLINO)METHYL)STYRYL)- 1 H-IMIDAZOL-6- YL)-5'-METHOXYSPIRO[CYCLOPROPANE-1,3'-INDOLIN]-2'-ONE FUMARATE 未知

公开(公告)号：SG11202111003UA

公开(公告)日：2021-11-29

申请号：SG11202111003U

申请日：2020-04-23

Applicant: UNIV HEALTH NETWORK

Inventor： LI SZE-WAN , BRAY MARK ROBERT

IPC: C07D413/10 , A61K31/191 , A61K31/5377 , A61P35/00 , C07C57/15

Abstract: Disclosed is Crystal Form S4 of a fumarate salt of compound (I) represented by the following structural formula: (I) The molar ratio between compound (I) and fumaric acid is 1.0:1:0. Crystal Form S4, 5 characterized by an X-ray powder diffraction pattern which comprises peaks at 6.6°, 9.8°, 16.3°, 21.1°, 28.7°, and 30.2° ± 0.2 in 2θ.

2.

发明专利
Crystal form S4 of the PLK4 inhibitor (1R,2S)-(E)-2-(3-(4-((cis-2,6-dimethylmorpholino)methyl)styryl)- 1 H-imidazol-6- yl)-5'-methoxyspiro(cyclopropane-1,3'-indolin)-2'-one fumarate 未知

公开(公告)号：AU2020264143A1

公开(公告)日：2021-10-28

申请号：AU2020264143

申请日：2020-04-23

Applicant: UNIV HEALTH NETWORK

Inventor： LI SZE-WAN , BRAY MARK ROBERT

IPC: C07D413/10 , A61K31/191 , A61K31/5377 , A61P35/00 , C07C57/15

Abstract: Disclosed is Crystal Form S4 of a fumarate salt of compound (I) represented by the following structural formula: (I) The molar ratio between compound (I) and fumaric acid is 1.0:1:0. Crystal Form S4, 5 characterized by an X-ray powder diffraction pattern which comprises peaks at 6.6°, 9.8°, 16.3°, 21.1°, 28.7°, and 30.2° ± 0.2 in 2θ.

3.

发明专利
COMBINATION THERAPIES FOR INHIBITION OF TTK PROTEIN KINASE 未知

公开(公告)号：CA3071001A1

公开(公告)日：2019-02-07

申请号：CA3071001

申请日：2018-08-01

Applicant: UNIV HEALTH NETWORK

Inventor： BRAY MARK ROBERT , MASON JACQUELINE M , MAK TAK W , FLETCHER GRAHAM

IPC: A61K31/519 , A61K39/395 , A61P35/00 , C07D487/04 , C07K16/18

Abstract: Provided herein are methods of treating cancer using an effective amount of a compound represented by the formula: (I) or a pharmaceutically acceptable salt thereof and an effective amount of an immune checkpoint inhibitor. Also provided are compositions comprising the same compound represented by the formula shown above or a pharmaceutically acceptable salt thereof and an immune checkpoint inhibitor.

4.

发明专利
FORME CRISTALLINE S4 D'UN INHIBITEUR DE PLK4 (1R,2S)-(E)-2-(3-(4-((CIS-2,6-DIMÉTHYLMORPHOLINO)MÉTHYL)STYRYL)- 1 H-IMIDAZOL-6- YL)-5'-MÉTHOXYSPIRO[CYCLOPROPANE-L,3'-INDOLIN]-2'-ONE FUMARATE 未知

公开(公告)号：MA55767A

公开(公告)日：2022-03-02

申请号：MA55767

申请日：2020-04-23

Applicant: UNIV HEALTH NETWORK

Inventor： BRAY MARK ROBERT , LI SZE-WAN

IPC: A61K31/191 , A61K31/5377 , A61P35/00 , C07C57/15 , C07D413/10

5.

发明专利
CRYSTAL FORM S4 OF THE PLK4 INHIBITOR (IR,2S)-(E)-2-(3-(4-((CIS-2,6-DIMETHYLMORPHOLINO)METHYL)STYRYL)- 1 H-IMIDAZOL-6-YL)-5'-METHOXYSPIRO[CYCLOPROPANE-L,3'-INDOLIN]-2'-ONE FUMARATE 未知

公开(公告)号：CA3137191A1

公开(公告)日：2020-10-29

申请号：CA3137191

申请日：2020-04-23

Applicant: UNIV HEALTH NETWORK

Inventor： LI SZE-WAN , BRAY MARK ROBERT

IPC: C07D413/10 , A61K31/191 , A61K31/5377 , A61P35/00 , C07C57/15

Abstract: Disclosed is Crystal Form S4 of a fumarate salt of compound (I) represented by the following structural formula: (I) The molar ratio between compound (I) and fumaric acid is 1.0:1:0. Crystal Form S4, 5 characterized by an X-ray powder diffraction pattern which comprises peaks at 6.6°, 9.8°, 16.3°, 21.1°, 28.7°, and 30.2° ± 0.2 in 2?.

6.

发明专利
Cytotoxic heteromeric protein combinatorial libraries 未知

公开(公告)号：AU769824B2

公开(公告)日：2004-02-05

申请号：AU1553099

申请日：1998-12-08

Applicant: UNIV HEALTH NETWORK

Inventor： GARIEPY JEAN , BRAY MARK ROBERT

IPC: G01N33/68 , A61K38/00 , A61K39/02 , A61P35/00 , C07K14/25 , C12N15/09 , C12N15/10 , C12Q1/02 , C12Q1/68 , A61K31/70

Abstract: A method is provided for constructing, identifying and using new therapeutic or diagnostic proteins capable of binding to a target cell. The new proteins are derived by mutating a binding subunit of a wild type heteromeric cytotoxic protein to create a library of microorganism clones producing mutant proteins which are then screened for their ability to specifically bind to and kill a target cell.

7.

发明专利
Crystal form s4 of the plk4 inhibitor (1r,2s)-(e)-2-(3-(4-((cis-2,6-dimethylmorpholino)methyl)styryl)- 1 h-imidazol-6- yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one fumarate 未知

公开(公告)号：IL287394D0

公开(公告)日：2021-12-01

申请号：IL28739421

申请日：2021-10-19

Applicant: UNIV HEALTH NETWORK , LI SZE WAN , BRAY MARK ROBERT

Inventor： LI SZE-WAN , BRAY MARK ROBERT

IPC: A61K31/5377 , A61P35/00

Abstract: Disclosed is Crystal Form S4 of a fumarate salt of compound (I) represented by the following structural formula: (I) The molar ratio between compound (I) and fumaric acid is 1.0:1:0. Crystal Form S4, 5 characterized by an X-ray powder diffraction pattern which comprises peaks at 6.6°, 9.8°, 16.3°, 21.1°, 28.7°, and 30.2° ± 0.2 in 2θ.

8.

发明专利
未知

公开(公告)号：AT337396T

公开(公告)日：2006-09-15

申请号：AT98959689

申请日：1998-12-08

Applicant: UNIV HEALTH NETWORK

Inventor： GARIEPY JEAN , BRAY MARK ROBERT

IPC: G01N33/68 , A61K38/00 , A61K39/02 , A61P35/00 , C07K14/25 , C12N15/09 , C12N15/10 , C12Q1/02 , C12Q1/68 , A61K31/70

Abstract: A method is provided for constructing, identifying and using new therapeutic or diagnostic proteins capable of binding to a target cell. The new proteins are derived by mutating a binding subunit of a wild type heteromeric cytotoxic protein to create a library of microorganism clones producing mutant proteins which are then screened for their ability to specifically bind to and kill a target cell.

9.

发明专利
Cytotoxic heteromeric protein combinatorial libraries 未知

公开(公告)号：AU1553099A

公开(公告)日：1999-08-23

申请号：AU1553099

申请日：1998-12-08

Applicant: UNIV HEALTH NETWORK

Inventor： GARIEPY JEAN , BRAY MARK ROBERT

IPC: G01N33/68 , A61K38/00 , A61K39/02 , A61P35/00 , C07K14/25 , C12N15/09 , C12N15/10 , C12Q1/02 , C12Q1/68 , A61K31/70

Abstract: A method is provided for constructing, identifying and using new therapeutic or diagnostic proteins capable of binding to a target cell. The new proteins are derived by mutating a binding subunit of a wild type heteromeric cytotoxic protein to create a library of microorganism clones producing mutant proteins which are then screened for their ability to specifically bind to and kill a target cell.

Patent Agency Ranking